Probably relates to what the FDA want to see for a breakthrough therapy designation.
What mechanism do you think Bisantrene was targeting to overcome therapy acquired resistance in the P2 relapsed/refractory pediatric AML BIS + ARA-C and P2 relapsed/refractory AML BIS + CLO + FLO combination trials? Plenty of preclinical data supporting FTO resensitizing resistant cancer to the therapy it was previously resistant to.
If it is not FTO, it is still significant.
RAC media coverage, page-2236
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.67 |
Change
-0.065(3.75%) |
Mkt cap ! $284.4M | |||
| Open | High | Low | Value | Volume |
| $1.71 | $1.71 | $1.67 | $18.04K | 10.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2000 | $1.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 5495 | 2 |
View Market Depth
| Last trade - 10.45am 24/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |